Łukasiewicz – Instytut Chemii Przemysłowej imienia Profesora Ignacego Mościckiego

Name

Łukasiewicz – Instytut Chemii Przemysłowej imienia Profesora Ignacego Mościckiego

Legal name

Sieć Badawcza Łukasiewicz – Instytut Chemii Przemysłowej imienia Profesora Ignacego Mościckiego

Website

https://ichp.lukasiewicz.gov.pl

Company type

Private

Founded year

1916

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Chemical Research and Development Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Chemical Manufacturing (325)

SIC

Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAHAB

Small-Molecule API Commercial Manufacturing

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAA

Small-Molecule API Process Development & Route Scouting

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAL

GMP Scale-Up, Tech Transfer & Process Validation (PPQ)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAM

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

• Applied chemical research
• Pharmaceutical API manufacturing
• Technology licensing services
• Polymer technology development
• Analytical testing services

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Commercial API Production: Manufacturing and sale of active pharmaceutical ingredients (APIs) to pharmaceutical companies. The institute is a key API manufacturer in the Polish market (second in production volume according to IQVIA) with 8 active pharmaceutical ingredients in portfolio.
2. Technology Licensing: Licensing of proprietary chemical and pharmaceutical technologies to industrial partners. Includes transfer of manufacturing processes and technical expertise.
3. Research and Analysis Services: Providing analytical testing, research services, and expertise to external clients in chemistry, pharmacy, and related fields.
4. Commercial Space Rental: Rental of modern office, laboratory, warehouse, and catering spaces at Rydygiera Street 8 in Warsaw's Żoliborz district.
5. R&D Project Funding (KPO): EU-funded research projects through National Recovery Plan (KPO) including Mościcki Campus development worth PLN 237,272,870 total cost with PLN 160,609,817 in KPO funding.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Łukasiewicz – Industrial Chemistry Institute is a Polish research institute that conducts applied research and development in chemistry, chemical technology, biotechnology, and pharmacy. It manufactures active pharmaceutical ingredients (APIs) under GMP, CEP, and ASMF standards, develops and licenses proprietary chemical and pharmaceutical technologies to industrial partners globally, and provides analytical testing, research services, and pilot-scale technology validation. It is a key API producer in the Polish market and operates research centers focused on low-emission technologies, polymer chemistry, and pharmaceutical product development.

Product overview

Łukasiewicz – Instytut Chemii Przemysłowej is a leading Polish research institute offering comprehensive solutions in applied and developmental research across chemistry, chemical technology, biotechnology, and pharmacy. The institute operates as a multi-disciplinary platform organized around four main research pillars: Chemical Technologies (including hydrogen and low-emission technologies, catalytic processes), Polymer Technologies (modern polymers and composites for energy-efficient applications), Cosmetic Chemistry and Biotechnology (pharmaceuticals, functional food, medical technologies), and Pharmaceutical Analytics (API research, GMP studies). The product portfolio includes two established pharmaceutical brands—BIODRIBIN® (anti-leukemia drug) and GENSULIN® (human insulin)—alongside a commercial API production offering (8 active pharmaceutical ingredients manufactured to GMP, CEP, and ASMF standards). The institute's infrastructure is augmented by three KPO-funded research centers: CeTeAPI (API Manufacturing Technology Center), CeProFarm (Pharmaceutical Products Development Center), and CeTeN (Low Emission Technologies Development Center), collectively known as the Mościcki Campus.

Differentiator

Problem solved

Functional benefit

Brands

• BIODRIBIN®: Anti-leukemia drug based on cladribine, produced at the Institute.
• CeTeAPI (Centrum Technologii Wytwarzania API)
• CeProFarm (Centrum Rozwoju Produktów Farmaceutycznych i Pokrewnych)
• CeTeN (Centrum Rozwoju Technologii Niskoemisyjnych)
• GENSULIN®

Products and services

• Active Pharmaceutical Ingredients (APIs)
• BIODRIBIN®
• GENSULIN® Technology Licensing
• Research and Analytical Testing Services
• Technology Licensing and Transfer
• Commercial Space Rental

Quantifiable outcome

• Second largest API manufacturer in Polish market by volume (IQVIA)
• +4 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature11 records

Partnerships

Ten partnerships are on record, tiered core and major.

• Łukasiewicz Research NetworkcoreStrategic or Co-development PartnerThe institute is an integral part of the Łukasiewicz Research Network, one of the largest research networks in Europe, consisting of 22 institutes with over 4,500 employees. The network provides shared resources, cross-institute collaboration, and collective market presence.
• Grupa AzotymajorStrategic or Co-development PartnerMajor Polish chemical conglomerate and key customer. Paweł Bielski, Vice-President of Grupa Azoty Management Board, serves on the Institute Council.
• VIVE Textile Recycling Sp. z o.o.majorStrategic or Co-development PartnerTextile recycling company with Piotr Brzeziński, Director of R&D, serving on the Institute Council representing this innovative partner.
• ORLEN Południe S.A.majorStrategic or Co-development PartnerPart of PKN ORLEN group. Grzegorz Semerjak, Director of Technology and Development at ORLEN Południe S.A., serves on the Institute Council and is Vice-President of Silesian-Małopolska Hydrogen Valley.
• Polish Chamber of Chemical IndustrymajorStrategic or Co-development PartnerTomasz Zieliński, President of the Board of Polish Chamber of Chemical Industry and member of Orlen S.A. Supervisory Board, serves on the Institute Council.
• Warsaw University of TechnologymajorStrategic or Co-development PartnerAcademic partner. Prof. Dr. Eng. Władysław Wieczorek (Dean of Faculty of Chemistry) serves as Council President. Prof. Marek Henczka (Dean of Faculty of Chemical and Process Engineering) serves as Council member.
• National Medicines InstitutemajorStrategic or Co-development PartnerDr. Małgorzata Kęsik-Brodacka, Deputy Director for Scientific Affairs at National Medicines Institute (prof. NIL), serves on the Institute Council.
• BASFmajorTechnology or IntegrationGlobal chemical company that purchased TDI production technology (TDA phosgenation process) from the institute in 2012.
• BIOTON S.A.majorTechnology or IntegrationPolish biopharmaceutical company that implemented institute's proprietary human insulin (GENSULIN®) production technology in 2000 - first Polish drug produced using genetic engineering.
• PKN Orlen S.A.majorTechnology or IntegrationPoland's largest oil refiner. Institute developed co-hydrogenation technology for diesel biocomponents delivered in 2019. Tomasz Zieliński from PKN Orlen serves on Institute Council.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Chemo (Insud Pharma): Spanish-headquartered integrated API and finished-dose manufacturer with a large European API portfolio. Comparable as a mid-sized European API/CDMO serving global pharma customers under similar regulatory standards.
• Polpharma: Poland's largest pharmaceutical manufacturer and a key IChP customer. Comparable as a domestic Polish API and finished-dose manufacturer with overlapping customer relationships and parallel drug-security positioning.
• BIOTON: Polish biopharmaceutical company and IChP partner that commercialized GENSULIN insulin technology in 2000. Comparable as a domestic Polish player in biopharma manufacturing with shared technology-licensing heritage.
• Centrient Pharmaceuticals: Dutch-headquartered producer of sustainable small-molecule APIs including beta-lactam antibiotics, statins, and anti-infectives. Comparable as a European API manufacturer with GMP-certified facilities serving global pharma customers.
• Adamed Pharma: Polish pharmaceutical company focused on cardiology, oncology, and CNS, listed as a key IChP customer. Comparable as a Polish pharma counterpart that depends on IChP APIs and shares the same domestic drug-security agenda.
• Siegfried Holding: Swiss-listed API and intermediates CDMO with global GMP manufacturing sites and a broad small-molecule API portfolio. Directly comparable as a European contract manufacturer serving pharma customers under similar regulatory frameworks (GMP, CEP, DMF/ASMF).
• EUROAPI: French API manufacturer spun out from Sanofi with one of the broadest small-molecule API portfolios in Europe and a strategic mission tied to European drug sovereignty. Directly comparable in scope (commercial API manufacturing + CDMO services) and policy positioning.
• Aenova: German-headquartered pharma CDMO offering API development, manufacturing, and finished dosage forms. Comparable as a European mid-sized CDMO with overlapping services in API development, GMP manufacturing, and contract research.
• Hovione: Portugal-headquartered API CDMO specializing in small-molecule API development and GMP manufacturing. Comparable as a privately held European CDMO with process development, scale-up, and regulatory support services mirroring the institute's offering.

Broad incumbents

• Lonza: Swiss-listed global leader in CDMO services across small molecules, biologics, and cell & gene. Comparable as a much larger European incumbent offering overlapping API development and GMP manufacturing capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/IChP_pl
• Facebookfacebook.com/LukasiewiczInstytutChemiiPrzemyslowej
• LinkedInlinkedin.com/company/lukasiewicz-instytut-chemii-przemyslowej

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Łukasiewicz – Instytut Chemii Przemysłowej imienia Profesora Ignacego Mościckiego